169 related articles for article (PubMed ID: 37897876)
1. Real-world super-response to biologics in severe asthma: A French monocentric retrospective cohort study.
Valéry S; Habib-Maillard S; Roche N
Respir Med Res; 2023 Nov; 84():101055. PubMed ID: 37897876
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
Fyles F; Nuttall A; Joplin H; Burhan H
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
Nanzer AM; Maynard-Paquette AC; Alam V; Green L; Thomson L; Lam J; Fernandes M; Roxas C; d'Ancona G; Hearn A; Gates J; Agarwal S; Kent BD; Fernando M; D'Cruz DP; Hopkins C; Ismail TF; Dhariwal J; Jackson DJ
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):724-732. PubMed ID: 38211889
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation.
Eger K; Kroes JA; Ten Brinke A; Bel EH
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1194-1200. PubMed ID: 33069885
[TBL] [Abstract][Full Text] [Related]
8. Treatments of refractory eosinophilic lung diseases with biologics.
Asano K; Suzuki Y; Tanaka J; Kobayashi K; Kamide Y
Allergol Int; 2023 Jan; 72(1):31-40. PubMed ID: 36333218
[TBL] [Abstract][Full Text] [Related]
9. Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma.
Menigoz C; Dirou S; Chambellan A; Hassoun D; Moui A; Magnan A; Blanc FX
J Asthma; 2023 Jun; 60(6):1162-1170. PubMed ID: 36301080
[TBL] [Abstract][Full Text] [Related]
10. [Anti-IL-5 in severe asthma associated with eosinophilic granulomatosis with polyangiitis. Real-life study].
Akdime F; Habib S; Regard L; Terrier B; Cohen P; Mouthon L; Guillevin L; Burgel PR; Honore I; Puéchal X; Roche N
Rev Mal Respir; 2023; 40(9-10):732-742. PubMed ID: 37923651
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience.
Özdel Öztürk B; Yavuz Z; Aydın Ö; Mungan D; Sin BA; Demirel YS; Bavbek S
Int Arch Allergy Immunol; 2022; 183(12):1281-1290. PubMed ID: 36126640
[TBL] [Abstract][Full Text] [Related]
12. Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
Portacci A; Campisi R; Buonamico E; Nolasco S; Pelaia C; Crimi N; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Scichilone N; Pelaia G; Crimi C; Carpagnano GE
ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37908397
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
[TBL] [Abstract][Full Text] [Related]
14. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness of IL-5/5Ra Targeted Biologics in Severe Eosinophilic Asthma With Comorbid Bronchiectasis.
Bendien SA; Kroes JA; van Hal LHG; Braunstahl GJ; Broeders MEAC; Oud KTM; Patberg KW; Smeenk FWJM; van Veen IHPAA; Weersink EJM; Fieten KB; Hashimoto S; van Veen A; Sont JK; van Huisstede A; van de Ven MJT; Langeveld B; Maitland-van der Zee AH; Ten Brinke A;
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2724-2731.e2. PubMed ID: 37295671
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of new adult users of mepolizumab with asthma in the USA.
Wu AC; McMahon PM; Welch E; McMahill-Walraven CN; Jamal-Allial A; Gallagher M; Zhang T; Draper C; Kline AM; Koerner L; Brown JS; Van Dyke MK
BMJ Open Respir Res; 2021 Nov; 8(1):. PubMed ID: 34732517
[TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma.
Kavanagh JE; d'Ancona G; Elstad M; Green L; Fernandes M; Thomson L; Roxas C; Dhariwal J; Nanzer AM; Kent BD; Jackson DJ
Chest; 2020 Aug; 158(2):491-500. PubMed ID: 32275980
[TBL] [Abstract][Full Text] [Related]
18. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
19. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort.
Milger K; Suhling H; Skowasch D; Holtdirk A; Kneidinger N; Behr J; Timmermann H; Schulz C; Schmidt O; Ehmann R; Hamelmann E; Idzko M; Taube C; Lommatzsch M; Buhl R; Korn S
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2701-2712.e2. PubMed ID: 37301433
[TBL] [Abstract][Full Text] [Related]
20. Biologics for eosinophilic granulomatosis with polyangiitis.
Caminati M; Maule M; Bello F; Emmi G
Curr Opin Allergy Clin Immunol; 2023 Feb; 23(1):36-43. PubMed ID: 36413432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
